Edward Parsons, MBA, PhD, Chief Operating Officer

Dr. Parsons led strategy and business development for a novel ophthalmic drug at Tyrogenex, and of Veracyte’s Percepta genomic test at Allegro Diagnostics. He was responsible for application development and clinical research of targeted in vivo imaging agents at Epix Pharmaceuticals and, after an the acquisition of its diagnostic assets, at Lantheus Medical Imaging.

Ed frequently serves as an advisor to investors and executives of small- and medium-sized companies. Working at the intersection of research and business strategy, he specializes in innovative product development. He holds an MBA from MIT’s Sloan School of Business and a PhD in Applied Physics from Yale University.